STOCK TITAN

ERPY - ERPY STOCK NEWS

Welcome to our dedicated news page for ERPY (Ticker: ERPY), a resource for investors and traders seeking the latest updates and insights on ERPY.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ERPY's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ERPY's position in the market.

Rhea-AI Summary
PHAXIAM Therapeutics announces high coverage performance of its two anti-Staphylococcus aureus phages over clinical strains.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
PHAXIAM has regained compliance with Nasdaq Listing Rule 5550(a)(2) after its closing bid price of American Depositary Shares (ADSs) remained above $1.00 per ADS for 10 consecutive business days from September 18 to September 29, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
PHAXIAM Therapeutics and Vetophage announce strategic research collaboration in the fight against antimicrobial resistance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
PHAXIAM provides business and financial update for the first half of 2023. Formation of PHAXIAM Therapeutics to create a global leader in phage therapies. Plan to launch new phase 2b/3 study in Prosthetic Joint Infections. Cash and cash equivalents of €25.2 million ($27.5 million) as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
PHAXIAM Therapeutics extends its phage portfolio to Klebsiella pneumoniae, a new resistant and aggressive bacterial target
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
PHAXIAM Therapeutics completes reverse share split, exchanging 10 existing shares for 1 new share. New shares listed on Euronext Paris. ADR holders required to exchange old ADSs for new ADSs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Monthly information related to total number of voting rights and shares composing the share capital as of August 31, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
PHAXIAM Therapeutics publishes cash position & financial calendar, announces participation at investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
ERPY

Nasdaq:ERPY

ERPY Rankings

ERPY Stock Data